Comparison of HAIC plus Targeted Immunotherapy and TACE plus Targeted Immunotherapy in Unresectable BCLC Stage C Hepatocellular Carcinoma with Up-to-11 High Tumor Burden: A Multicenter Retrospective Study
In a multicenter retrospective study of unresectable BCLC stage C hepatocellular carcinoma patients with high tumor burden, HAIC combined with targeted immunotherapy demonstrated significantly prolonged progression-free survival and reduced mild local adverse events compared to TACE plus targeted immunotherapy, while showing comparable overall survival and response rates.